Drug Profile
YHD 001
Alternative Names: YHD001Latest Information Update: 08 Sep 2015
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antibronchitics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Bronchitis
Most Recent Events
- 08 Sep 2015 Discontinued - Phase-II for Asthma and Bronchitis in South Korea (PO)
- 01 Jan 2014 Yuhan Corporation completes a phase II trial in Asthma in South Korea (NCT01424124)
- 23 Feb 2012 Yuhan Corporation completes enrolment in its phase II trial for Bronchitis in South Korea (NCT01420445)